Cipla Limited has submitted a regulatory disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the outcome of a USFDA inspection at its manufacturing facility.
The United States Food and Drug Administration (USFDA) conducted a follow-up current Good Manufacturing Practices (cGMP) inspection at the Company's manufacturing facility located in Pithampur, India. The inspection period was from 17th August 2026 to 25th August 2026.
This inspection represents a follow-up to previous inspections on the same subject, as referenced in the company's earlier intimations dated 18th February 2023, 5th August 2023, and 18th November 2023.
Upon conclusion of the inspection, the Company received seven (7) inspectional observations documented in Form 483. The Company has stated that it will work closely with the USFDA and is committed to addressing these observations comprehensively within the stipulated timeframe.
The disclosure was signed by Rajendra Chopra, Company Secretary, and prepared by Chirag Hotchandani. The document was addressed to BSE Ltd., National Stock Exchange of India Ltd., and Societe De La Bourse De Luxemburg.
Financial impact of the observations was not quantified in the disclosure.